Trial of nemolizumab in moderate-to-severe prurigo nodularis
S Ständer, G Yosipovitch, FJ Legat… - … England Journal of …, 2020 - Mass Medical Soc
Background Prurigo nodularis is a chronic pruritic skin disease with multiple nodular skin
lesions. Nemolizumab is a monoclonal antibody targeting the interleukin-31 receptor, which …
lesions. Nemolizumab is a monoclonal antibody targeting the interleukin-31 receptor, which …
[PDF][PDF] Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis
S Ständer, G Yosipovitch, FJ Legat, JP Lacour… - N Engl J …, 2020 - allergieundhaut.ch
Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis Page 1 The new england
journal of medicine n engl j med 382;8 nejm.org February 20, 2020 706 From the …
journal of medicine n engl j med 382;8 nejm.org February 20, 2020 706 From the …
[引用][C] Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis
S Ständer, G Yosipovitch, FJ Legat, JP Lacour… - New England Journal …, 2020 - cir.nii.ac.jp
Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis | CiNii Research CiNii 国立
情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす …
情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす …
Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis
S Staender, G Yosipovitch, FJ Legat… - New England …, 2020 - epub.ub.uni-muenchen.de
Background: Prurigo nodularis is a chronic pruritic skin disease with multiple nodular skin
lesions. Nemolizumab is a monoclonal antibody targeting the interleukin-31 receptor, which …
lesions. Nemolizumab is a monoclonal antibody targeting the interleukin-31 receptor, which …
[HTML][HTML] Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis
S Ständer, G Yosipovitch, FJ Legat… - The New England …, 2020 - scholarship.miami.edu
Abstract Adult Aged Aged, 80 and over Antibodies, Monoclonal, Humanized-adverse effects
Antibodies, Monoclonal, Humanized-therapeutic use Double-Blind Method Female …
Antibodies, Monoclonal, Humanized-therapeutic use Double-Blind Method Female …
Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.
S Ständer, G Yosipovitch, FJ Legat… - The New England …, 2020 - europepmc.org
BACKGROUND: Prurigo nodularis is a chronic pruritic skin disease with multiple nodular
skin lesions. Nemolizumab is a monoclonal antibody targeting the interleukin-31 receptor …
skin lesions. Nemolizumab is a monoclonal antibody targeting the interleukin-31 receptor …
Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis
S Ständer, G Yosipovitch, FJ Legat… - The New England …, 2020 - pubmed.ncbi.nlm.nih.gov
Background Prurigo nodularis is a chronic pruritic skin disease with multiple nodular skin
lesions. Nemolizumab is a monoclonal antibody targeting the interleukin-31 receptor, which …
lesions. Nemolizumab is a monoclonal antibody targeting the interleukin-31 receptor, which …